Breast Oncology Program
- Institution
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA
- Principal investigator
- Andrei Goga
- Funding
- $186K
- Duration
- 1999–2028
Moonbase score
Still being scored
Abstract
Breast Oncology Program: Summary/Abstract The goal of the HDFCCC Breast Oncology (BR) Program is to reduce the risk of breast cancer development, progression, and mortality using innovative approaches and novel methodologies to reveal the molecular, cellular, and targetable networks that underlie susceptibility, heterogeneity, and outcome disparities. The translational nature of the program means that laboratory-based work in the program can be rapidly moved into clinical trials. The clinical research of the BR Program includes reducing overdiagnosis, over- and under- treatment, and the burden of cancer therapy through risk assessment to individualize screening and prevention measures, and through improved tumor classification to tailor treatment. BR research focuses on three areas: (1) understanding how tumor heterogeneity contributes to metastasis, dormancy, and therapeutic resistance; (2) developing new therapeutic strategies using innovation in trial design and drug development; and (3) better characterizing early breast lesions to improve screening, prevention, and health care value.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of California, San FranciscoNot yet scored
Understanding CDK1 Function and Cancer Vulnerabilities
Andrei Goga · $484K · 2023–2028
- NIH · University of California, San Francisco66
Dendrite development, function, degeneration and regeneration
Yuh Nung Jan · $676K · 2024–2032
- NIH · University of California, San Francisco64
Dissecting Mechanism of Neurofibromin Regulation in the Context of Sporadic Cancers and Neurofibromatosis Type 1
Madeleine Janette Sitton · $94K · 2024–2028